Asthma Clinical Trial
— SMARTASIAOfficial title:
Real Life Effectiveness of Symbicort Maintenance and Reliever Therapy (SMART) in Asthma Patients Across Asia: SMARTASIA
The purpose of this study is to compare whether Symbicort Maintenance & Reliever Therapy (SMART) is more effective in uncontrolled asthmatic patients than their current therapy in a real life situation.
Status | Completed |
Enrollment | 862 |
Est. completion date | August 2010 |
Est. primary completion date | August 2010 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | 18 Years and older |
Eligibility |
Inclusion Criteria: - Provision of signed informed consent - Asthma diagnosis at least 6 months before visit 1 of study - Patients who have reversible airway obstruction continuous asthma treatment except Symbicort at least within 4 weeks before visit 1 of study Exclusion Criteria: - Known or suspected allergy to active ingredients of study medication or excipients - Use of oral, rectal or parenteral glucocorticosteroids 30 days before visit 1 of study - Smoking, current or previous with a smoking history of = 10 pack years |
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
China | Research Site | Beijing | |
China | Research Site | Changsha | Hunan |
China | Research Site | Chengdu | |
China | Research Site | Fuzhou | |
China | Research Site | Guangzhou | Guangdong |
China | Research Site | Hangzhou | |
China | Research Site | Nanjing | |
China | Research Site | Qingdao | Shandong |
China | Research Site | Shanghai | Shanghai |
China | Research Site | Shenyang | |
China | Research Site | Wuhan | Hubei |
China | Research Site | Zheng Ahou | He Nan |
China | Research Site | Zhengzhou | |
India | Research Site | Ahmedabad | Gujarat |
India | Research Site | Bangalore | Karnataka |
India | Research Site | Bengaluru | Karnataka |
India | Research Site | Chennai | Tamil Nadu |
India | Research Site | Coimbatore | Tamil Nadu |
India | Research Site | Hyderabad | Andhra Pradesh |
India | Research Site | Indore | Madhya Pradesh |
India | Research Site | Lucknow | Uttar Pradesh |
India | Research Site | Mumbai | Maharashtra |
India | Research Site | Noida | Uttar Pradesh |
Indonesia | Research Site | Jakarta | DKI Jakarta |
Indonesia | Research Site | Surabaya | East Java |
Taiwan | Research Site | Chia-Yi | |
Taiwan | Research Site | Hsin Chu | |
Taiwan | Research Site | Kaohsiung | |
Taiwan | Research Site | Taichung | |
Taiwan | Research Site | Taipei | |
Taiwan | Research Site | Taoyuan City | |
Thailand | Research Site | Bangkok | |
Thailand | Research Site | Nakhonratchasima | Naimuang |
Thailand | Research Site | Pathumthani | |
Thailand | Research Site | Pathumwan | Bangkok |
Lead Sponsor | Collaborator |
---|---|
AstraZeneca |
China, India, Indonesia, Taiwan, Thailand,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Change in Asthma Control Questionnaire (ACQ(5)) Score From Baseline at a Regional Level | Participants' levels of asthma control were scored on a 7-point Likert scale from 0 to 6, whereby 0 represents good control and 6 represents poor control of asthma. The regional mean change of overall ACQ(5) score were calculated as change from baseline (Week 0) to the average during the treatment period (mean of scores at Week 4, Week 8, Week 12). | Baseline and 12 weeks | No |
Secondary | Change in ACQ(5) Score From Baseline at Country Level (China) | Participants' levels of asthma control were scored on a 7-point Likert scale from 0 to 6, whereby 0 represents good control and 6 represents poor control of asthma. The regional mean change of overall ACQ(5) score were calculated as change from baseline (Week 0) to the average during the treatment period (mean of scores at Week 4, Week 8, Week 12). | Baseline and 12 weeks | No |
Secondary | Change in Overall ACQ(5) Score From Baseline at Country Level (India) | Participants' levels of asthma control were scored on a 7-point Likert scale from 0 to 6, whereby 0 represents good control and 6 represents poor control of asthma. The regional mean change of overall ACQ(5) score were calculated as change from baseline (Week 0) to the average during the treatment period (mean of scores at Week 4, Week 8, Week 12). | Baseline and 12 weeks | No |
Secondary | Change in Overall ACQ(5) Score From Baseline at Country Level (Indonesia) | Participants' levels of asthma control were scored on a 7-point Likert scale from 0 to 6, whereby 0 represents good control and 6 represents poor control of asthma. The regional mean change of overall ACQ(5) score were calculated as change from baseline (Week 0) to the average during the treatment period (mean of scores at Week 4, Week 8, Week 12). | Baseline and 12 weeks | No |
Secondary | Change in Overall ACQ(5) Score From Baseline at Country Level (Taiwan) | Participants' levels of asthma control were scored on a 7-point Likert scale from 0 to 6, whereby 0 represents good control and 6 represents poor control of asthma. The regional mean change of overall ACQ(5) score were calculated as change from baseline (Week 0) to the average during the treatment period (mean of scores at Week 4, Week 8, Week 12). | Baseline and 12 weeks | No |
Secondary | Change in Overall ACQ(5) Score From Baseline at Country Level (Thailand) | Participants' levels of asthma control were scored on a 7-point Likert scale from 0 to 6, whereby 0 represents good control and 6 represents poor control of asthma. The regional mean change of overall ACQ(5) score were calculated as change from baseline (Week 0) to the average during the treatment period (mean of scores at Week 4, Week 8, Week 12). | Baseline and 12 weeks | No |
Secondary | Change in Asthma Quality of Life Questionnaire, Standardized Version (AQLQ (S)) Overall Scores From Baseline | Participants' QOL were scored on a scale of decreasing QOL impairment from 1 to 7, in which 1 = maximum impairment. The change in overall mean AQLQ(S) score from baseline were calculated as change from baseline (Week 0) to the average during the treatment period (mean of scores at Week 4, Week 8, Week 12) | Baseline and 12 weeks | No |
Secondary | Change in AQLQ (S) Domain (Symptom) Scores From Baseline | Participants' QOL were scored on a scale of decreasing QOL impairment from 1 to 7, in which 1 = maximum impairment. The change in overall mean AQLQ(S) symptom score were calculated as change from baseline (Week 0) to the average during the treatment period (mean of scores at Week 4, Week 8, Week 12). | Baseline and 12 weeks | No |
Secondary | Change in AQLQ (S) Domain (Activity Limitation) Scores From Baseline | Participants' QOL were scored on a scale of decreasing QOL impairment from 1 to 7, in which 1 = maximum impairment. The change in overall mean AQLQ(S) symptom score from baseline were calculated as change from baseline (Week 0) to the average during the treatment period (mean of scores at Week 4, Week 8, Week 12) | Baseline and 12 weeks | No |
Secondary | Change in AQLQ (S) Domain (Emotion Function) Scores From Baseline | Participants' emotional functions were scored on a scale of decreasing impairment to emotional function from 1 to 7, in which 1 = maximum impairment. The change in overall mean AQLQ(S) emotion function score were calculated as change from baseline (Week 0) to the treatment period (mean of the scores at Week 4, Week 8, Week 12) | Baseline and 12 weeks | No |
Secondary | Change in AQLQ (S) Domain (Environmental Stimuli) Scores From Baseline | Participants ' responses to environmental stimuli were scored on a scale of decreasing response to environmental stimuli from 1 to 7, in which 1 = maximum response. The change in overall mean AQLQ(S) score were calculated as change from baseline (Week 0) to the average during the treatment period (mean of scores at Week 4, Week 8, Week 12) | Baseline and 12 weeks | No |
Secondary | Study Medication Use (Maintenance and Reliever) in Diary Cards - Change in As-needed Day-time Reliever Medication From run-in Period | Change in the number of as-needed day-time inhalations of medication, defined as the difference in mean value of all available data obtained during treatment period and mean value in run-in period. | Baseline and 12 weeks | No |
Secondary | Study Medication Use (Maintenance and Reliever) in Diary Cards - Change in As-needed Night-time Reliever Medication From run-in Period | Change in the number of as-needed night-time inhalations of medication, calculated as difference in mean value of all available data obtained during treatment period and mean value in run-in period. | Baseline and 12 weeks | No |
Secondary | Study Medication Use (Maintenance and Reliever) in Diary Cards - Total Number of Inhalations of Symbicort® 160µg/4.5µg Per Day During Treatment Period | Total number of inhalations of Symbicort® 160µg/4.5µg per day during treatment period, defined as the sum of maintenance medication and as-needed medication during night and day time | Baseline and 12 weeks | No |
Secondary | Study Medication Use (Maintenance and Reliever) in Diary Cards - Percentage of Days During Treatment Period Participants Used = 3 Inhalations of Symbicort® 160µg/4.5µg in a Day | The mean percentage of days during treatment period participants used = 3 inhalations of Symbicort® 160µg/4.5µg in a day | Baseline and 12 weeks | No |
Secondary | Study Medication Use (Maintenance and Reliever) in Diary Cards - Percentage of Days During Treatment Period Participants Used = 5 Inhalations of of Symbicort® 160µg/4.5µg in a Day | The mean percentage of days during treatment period participants used = 5 inhalations of Symbicort® 160µg/4.5µg in a day | Baseline and 12 weeks | No |
Secondary | Study Medication Use (Maintenance and Reliever) in Diary Cards - Percentage of Days During Treatment Period Participants Used = 9 Inhalations of Symbicort® 160µg/4.5µg in a Day | The mean percentage of days during treatment period participants used = 9 inhalations of Symbicort® 160µg/4.5µg in a day | Baseline and 12 weeks | No |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT04410523 -
Study of Efficacy and Safety of CSJ117 in Patients With Severe Uncontrolled Asthma
|
Phase 2 | |
Completed |
NCT04624425 -
Additional Effects of Segmental Breathing In Asthma
|
N/A | |
Active, not recruiting |
NCT03927820 -
A Pharmacist-Led Intervention to Increase Inhaler Access and Reduce Hospital Readmissions (PILLAR)
|
N/A | |
Completed |
NCT04617015 -
Defining and Treating Depression-related Asthma
|
Early Phase 1 | |
Recruiting |
NCT03694158 -
Investigating Dupilumab's Effect in Asthma by Genotype
|
Phase 4 | |
Terminated |
NCT04946318 -
Study of Safety of CSJ117 in Participants With Moderate to Severe Uncontrolled Asthma
|
Phase 2 | |
Completed |
NCT04450108 -
Vivatmo Pro™ for Fractional Exhaled Nitric Oxide (FeNO) Monitoring in U.S. Asthmatic Patients
|
N/A | |
Completed |
NCT03086460 -
A Dose Ranging Study With CHF 1531 in Subjects With Asthma (FLASH)
|
Phase 2 | |
Completed |
NCT01160224 -
Oral GW766944 (Oral CCR3 Antagonist)
|
Phase 2 | |
Completed |
NCT03186209 -
Efficacy and Safety Study of Benralizumab in Patients With Uncontrolled Asthma on Medium to High Dose Inhaled Corticosteroid Plus LABA (MIRACLE)
|
Phase 3 | |
Completed |
NCT02502734 -
Effect of Inhaled Fluticasone Furoate on Short-term Growth in Paediatric Subjects With Asthma
|
Phase 3 | |
Completed |
NCT01715844 -
L-Citrulline Supplementation Pilot Study for Overweight Late Onset Asthmatics
|
Phase 1 | |
Terminated |
NCT04993443 -
First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036
|
Phase 1 | |
Completed |
NCT02787863 -
Clinical and Immunological Efficiency of Bacterial Vaccines at Adult Patients With Bronchopulmonary Pathology
|
Phase 4 | |
Recruiting |
NCT06033833 -
Long-term Safety and Efficacy Evaluation of Subcutaneous Amlitelimab in Adult Participants With Moderate-to-severe Asthma Who Completed Treatment Period of Previous Amlitelimab Asthma Clinical Study
|
Phase 2 | |
Completed |
NCT03257995 -
Pharmacodynamics, Safety, Tolerability, and Pharmacokinetics of Two Orally Inhaled Indacaterol Salts in Adult Subjects With Asthma.
|
Phase 2 | |
Completed |
NCT02212483 -
Clinical Effectiveness and Economical Impact of Medical Indoor Environment Counselors Visiting Homes of Asthma Patients
|
N/A | |
Recruiting |
NCT04872309 -
MUlti-nuclear MR Imaging Investigation of Respiratory Disease-associated CHanges in Lung Physiology
|
||
Withdrawn |
NCT01468805 -
Childhood Asthma Reduction Study
|
N/A | |
Recruiting |
NCT05145894 -
Differentiation of Asthma/COPD Exacerbation and Stable State Using Automated Lung Sound Analysis With LungPass Device
|